Silence Therapeutics (SLN) has released an update.
Silence Therapeutics has reported promising outcomes from its Phase 1 SANRECO study of divesiran in polycythemia vera patients, showing elimination of phlebotomy requirements in well-controlled individuals and a good safety profile. The data supports the progression of divesiran into Phase 2 trials. With its potential as the first siRNA therapy for this condition, divesiran demonstrates sustained reduction in hematocrit and favorable effects on iron metabolism indicators.
For further insights into SLN stock, check out TipRanks’ Stock Analysis page.
